loading...| Preferred Name |
tesamorelin |
|
| Synonyms |
|
|
| ID |
http://purl.obolibrary.org/obo/dinto_DB08869 |
|
| ATCCode |
H01AC06 |
|
| binds | ||
| CASRN |
901758-09-6 |
|
| DBBrand |
egrifta |
|
| DBSynonym |
tesamorelin acetate nda 22-505 th-9507 n-(trans-3-hexenoyl)-human growth hormone releasing factor (1-44) acetate th9507 th-9507 acetate egrifta |
|
| Definition |
Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection. |
|
| has pharmacological target | ||
| label |
tesamorelin |
|
| prefixIRI |
obo2:dinto_DB08869 |
|
| prefLabel |
tesamorelin |
|
| xref |
ChEBI:63626 UniProtKB:P01286 RxList:http://www.rxlist.com/egrifta-drug.htm PDRhealth:http://www.pdr.net/drug-summary/egrifta?druglabeli Wikipedia:http://en.wikipedia.org/wiki/Tesamorelin Drugs.com:http://www.drugs.com/egrifta.html National Drug Code Directory:44087-2010-3 |
|
| subClassOf |